Cargando…

Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study

Many people with sickle cell disease (SCD) or other anemias require chronic blood transfusions, which often causes iron overload that requires chelation therapy. The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwiatkowski, Janet L., Hamdy, Mona, El-Beshlawy, Amal, Ebeid, Fatma S. E., Badr, Mohammed, Alshehri, Abdulrahman, Kanter, Julie, Inusa, Baba, Adly, Amira A. M., Williams, Suzan, Kilinc, Yurdanur, Lee, David, Tricta, Fernando, Elalfy, Mohsen S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864642/ https://www.ncbi.nlm.nih.gov/pubmed/34847228 http://dx.doi.org/10.1182/bloodadvances.2021004938

Ejemplares similares

Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years
por: Elalfy, Mohsen S., et al.
Publicado: (2022)

S120: RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF DEFERIPRONE: SUBGROUP ANALYSIS OF PEDIATRIC PATIENTS IN IRON-OVERLOADED PATIENTS WITH SICKLE CELL DISEASE AND OTHER ANEMIAS
por: Inusa, B, et al.
Publicado: (2022)

S115: LONG-TERM EFFICACY AND SAFETY OF DEFERIPRONE FOR PATIENTS WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
por: Inusa, B, et al.
Publicado: (2022)

S123: SAFETY AND EFFICACY OF EARLY-START DEFERIPRONE IN INFANTS AND YOUNG CHILDREN WITH BETA-THALASSEMIA (START STUDY)
por: Elalfy, M, et al.
Publicado: (2022)

Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254.
Publicado: (2023)

The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study
por: Badawy, Sherif M., et al.
Publicado: (2021)

Chelation Therapy with Oral Solution of Deferiprone in Transfusional Iron-Overloaded Children with Hemoglobinopathies
por: Makis, Alexandros, et al.
Publicado: (2013)

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
por: Smith, Gillian C, et al.
Publicado: (2011)

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2007)

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy
por: Pepe, Alessia, et al.
Publicado: (2013)

Management of transfusional iron overload – differential properties and efficacy of iron chelating agents
por: Kwiatkowski, Janet L
Publicado: (2011)

Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major
por: Alpendurada, Francisco, et al.
Publicado: (2012)

Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
por: Ansari, Shahla, et al.
Publicado: (2017)

Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone
por: Porter, John B, et al.
Publicado: (2013)

Deferiprone‐induced agranulocytosis: 20 years of clinical observations
por: Tricta, Fernando, et al.
Publicado: (2016)

Treating thalassemia major-related iron overload: the role of deferiprone
por: Berdoukas, Vasilios, et al.
Publicado: (2012)

Effects of renal impairment on the pharmacokinetics of orally administered deferiprone
por: Fradette, Caroline, et al.
Publicado: (2016)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
por: Piga, A., et al.
Publicado: (2022)

Transfusional Iron Overload in a Cohort of Children with Sickle Cell Disease: Impact of Magnetic Resonance Imaging, Transfusion Method, and Chelation
por: Stanley, Helen M., et al.
Publicado: (2016)

P1442: PRACTICE-BASED EVIDENCE: LONG-TERM SAFETY COHORT OF DEFERIPRONE IN PATIENTS WITH SICKLE CELL DISEASE FROM THE US REGISTRY
por: Badawy, Sherif, et al.
Publicado: (2023)

The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes
por: Petrou, Emmanouil, et al.
Publicado: (2015)

PB2565: TRANSFUSIONAL IRON OVERLOAD AND ASSOCIATED COMPLICATIONS IN HEMATOLOGY DISORDERS PATIENTS
por: Romanenko, Nikolay, et al.
Publicado: (2023)

Comparative Efficacy and Safety of Deferoxamine, Deferiprone and Deferasirox on Severe Thalassemia: A Meta-Analysis of 16 Randomized Controlled Trials
por: Xia, Sujian, et al.
Publicado: (2013)

Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2011)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease
por: Soulières, Denis, et al.
Publicado: (2022)

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
por: Gattermann, Norbert
Publicado: (2008)

The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia
por: Kontoghiorghes, George J., et al.
Publicado: (2020)

Medicina transfusional
Publicado: (2010)

Medicina transfusional
Publicado: (2006)

Medicina transfusional

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
por: Kontoghiorghe, Christina N, et al.
Publicado: (2016)

Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review
por: Salem, Ahmed, et al.
Publicado: (2023)

Medicina transfusional : patient blood management /
Publicado: (2019)

Transfusional iron overload and intravenous iron infusions modify the mouse gut microbiota similarly to dietary iron
por: La Carpia, Francesca, et al.
Publicado: (2019)

Ameliorating Iron Overload in Intestinal Tissue of Adult Male Rats: Quercetin vs Deferoxamine
por: El-Sheikh, Arwa A., et al.
Publicado: (2018)

PEGylation of Deferoxamine for Improving the Stability, Cytotoxicity, and Iron-Overload in an Experimental Stroke Model in Rats
por: Xu, Jiake, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_07e98jiv1mterdsjqehcofrpp3